Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3422]

New CAR T therapy for relapsed and refractory ALL

Dr Claire Roddie - University College London, London, UK

$New CAR T therapy for relapsed and refractory ALL ( Dr Claire Roddie - University College London, London, UK )$

IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma

Prof Philippe Moreau - University of Nantes, Nantes, France

IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma ( Prof Philippe Moreau - University of Nantes, Nantes, France )

The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with...

Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain

The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with blinatumomab ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )

BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute...

Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain

BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute lymphoblastic leukaemia ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )

Preclinical models for small-cell lung cancer

Prof Anton Berns - Netherlands Cancer Institute, Amsterdam, Netherlands

Preclinical models for small-cell lung cancer ( Prof Anton Berns - Netherlands Cancer Institute, Amsterdam, Netherlands )

Early safety from a trial of talimogene laherparepvec (T-VEC) injected into...

Prof J. Randy Hecht - UCLA Jonsson Comprehensive Cancer Center, Santa Monica...

Early safety from a trial of talimogene laherparepvec (T-VEC) injected into liver tumours plus pembrolizumab ( Prof J. Randy Hecht - UCLA Jonsson Comprehensive Cancer Center, Santa Monica, USA )

CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer

Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA

CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer ( Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA )

Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma

Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA

$Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma ( Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA )$

Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin...

Dr John Kuruvilla - Princess Margaret Cancer Centre, Toronto, Canada

$Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin lymphoma ( Dr John Kuruvilla - Princess Margaret Cancer Centre, Toronto, Canada )$

FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO...

Prof Robert Huddart and Dr Ignacio Durán

FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO 2020 ( Prof Robert Huddart and Dr Ignacio Durán )

Perioperative chemotherapy with mFOLFIRINOX vs gemcitabine/nab-paclitaxel for...

Prof Davendra Sohal - University of Cincinnati, Cincinnati, USA

Perioperative chemotherapy with mFOLFIRINOX vs gemcitabine/nab-paclitaxel for resectable pancreatic ductal adenocarcinoma ( Prof Davendra Sohal - University of Cincinnati, Cincinnati, USA )

ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for...

Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia

ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients with Waldenström macroglobulinemia ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )

More from ecancer